Finamed

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finamed

Property Description
Active ingredient Finasteride
Form Oral film-coated tablets
Pharmacological class 5-alpha reductase inhibitor
General purpose Modulates androgen hormone metabolism
Origin Synthetic compound (4-aza-steroid)

What Type of Medication is Finamed?

Finamed is a prescription-only medication (Rx) containing the active ingredient Finasteride, which is provided in the dosage form of oral film-coated tablets. This drug is classified as a single-ingredient product, intended for systemic absorption upon ingestion. Finasteride is a synthetic compound known chemically as a 4-aza-steroid, a structure distinct from naturally occurring steroids. The film-coating on the tablets represents a distinctive formulation feature.

The Pharmacological Class of Finasteride

The core classification of Finasteride places it in the pharmacological class of 5-alpha reductase inhibitors (5-ARI). This positioning also broadly categorizes the substance as an antiandrogen. Finasteride functions as an enzyme inhibitor, primarily targeting the Type II 5-alpha reductase enzyme with high specificity. This specific enzymatic action is clinically recognized as a standard therapeutic approach within endocrinology.

Finamed's General Physiological Purpose

Finamed's general purpose is to act as an androgen hormone metabolism modulator within adult males by regulating the influence of potent androgens. Its action leads to a direct and measurable reduction of dihydrotestosterone (DHT) levels by preventing the hormone conversion. The outcome of this targeted mechanism is to help modulate or normalize specific biological conditions that are sensitive to excessive DHT activity, such as maintaining healthy androgen-dependent tissues.

Regulatory References

  1. European Medicines Agency (EMA)
  2. NIH StatPearls

What side effects are possible with Finamed?

Possible Side Effects and Safety Information

The safety profile of Finamed (Finasteride) is defined by officially documented adverse reactions categorized by frequency and the physiological systems affected.

Adverse reactions classified as common in regulatory documents often involve the Reproductive System and Breast Disorders (System-Organ Class, SOC). These include decreased libido (sexual desire), erectile dysfunction, ejaculation disorder, and a decreased volume of ejaculate. Less frequent but documented effects include breast enlargement (gynecomastia) and breast tenderness.

Postmarketing surveillance reports have identified adverse events in the Psychiatric Disorders category, such as depression and suicidal ideation, and in the Skin and Subcutaneous Tissue Disorders, including rash, urticaria (hives), and angioedema (swelling of the face or throat). These reports are generally assigned a frequency of not known.

Serious adverse reactions documented in official labels include rare reports of male breast cancer. Furthermore, an increased risk of high-grade prostate cancer (Gleason score 8–10) was observed in men receiving the 5 mg dose during a specific clinical trial.

Population and Duration Notes:

Finamed is explicitly contraindicated in pregnant women due to the potential risk of causing external genital abnormalities in a male fetus. A key safety note in the regulatory text is the possibility for certain sexual side effects, including decreased libido and erectile dysfunction, to persist after discontinuation of therapy.

Safety-Related Limitations:

The medicine is known to cause a predictable reduction of approximately 50% in serum Prostate-Specific Antigen (PSA) levels. Regulatory guidance specifies that PSA values must be doubled for accurate comparison with normal reference ranges for screening purposes.

Overdose and Emergency Response

The official regulatory documentation for Finamed (Finasteride) establishes a distinct overdose profile that is based primarily on data from clinical studies. These investigations exposed humans to doses significantly exceeding the typical therapeutic range, including single doses up to 400, mg and chronic doses up to 80, mg per day for three months. These trials demonstrated a noteworthy absence of specific clinical signs, symptoms, or documented adverse effects. Furthermore, regulatory authorities have concluded that no serious adverse events or life-threatening sequelae were observed even at these maximal tested doses. There are no population-specific overdose notes provided in the official labeling.

Despite the high dose tolerance observed in clinical data, the official guidance mandates that any suspected or confirmed overdose event must be addressed immediately. The required action is to seek immediate medical attention. This instruction is necessary because regulatory documents explicitly state that no specific antidote is known for Finasteride. Therefore, the prescribed management for a Finamed overdose consists solely of providing symptomatic and supportive treatment under appropriate medical supervision. This approach defines the emergency response required by the regulatory standard.

Therapeutic Uses of Finamed

What Finamed Treats: Main Uses and Benefits

Finamed is commonly used for managing two distinct, long-term conditions in adult males. The medication is used in areas where additional symptomatic support is needed, specifically for Benign Prostatic Hyperplasia (BPH) and Androgenetic Alopecia (AGA) (hereditary male pattern hair loss).


Therapeutic Application Overview

The medication is applied across domains where additional symptomatic support is needed, such as in situations involving noticeable Lower Urinary Tract Symptoms (LUTS), including urinary stream weakness and nocturia. It is also relevant for easing symptoms related to the gradual thinning and loss of hair on the scalp. This long-term management supports the patient during difficult episodes by easing distress and assists with maintaining functional stability related to appearance and urinary comfort.

“The medication is applied in clinical settings that involve chronic, progressive symptoms where supportive management is appropriate.”

Quick Fact: Symptom Support Context Finamed may assist with managing LUTS associated with an enlarged prostate and contributes to easing the symptom load related to progressive male pattern hair thinning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official eligibility profile for Finamed is strictly defined by regulatory bodies, establishing population boundaries for its use.

Eligibility Scope Status Defined by Regulators
Allowed Population Adult males (Aged 18 years and older). No age-related dosage adjustments are required for older adults or for patients with renal impairment.
Absolute Contraindications Females, including women who are or may potentially be pregnant. Finamed is also contraindicated for individuals with known hypersensitivity to the active ingredient or excipients, or those with certain rare hereditary problems such as lactose/galactose malabsorption.
Age and Gender Restriction Use is not indicated for females or for pediatric patients (under 18 years) as safety and efficacy have not been established in these groups.
Conditional Use Caution is advised when administering the medicine to patients with hepatic impairment (liver function abnormalities) due to the drug's metabolism in the liver.

Eligibility-Related Restrictions: Pregnant women or those who may become pregnant must not handle crushed or broken tablets, as the possibility of skin absorption presents a potential risk to a male fetus.

Connection to the overall eligibility profile: Regulatory documents classify Finamed as a treatment intended for men only, enforcing an absolute non-eligibility status for all women, particularly during pregnancy, and for children. These formal restrictions serve as the official, necessary boundaries for the medicine’s labeled use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Finamed's interaction profile is based on official government regulatory documents that define specific medicinal products, classes, and substance categories that should not be combined or require close monitoring.

Documented Interaction Categories and Management

Interaction Category Practical Regulatory Implication
Monoamine Oxidase Inhibitors (MAOIs) Strictly Contraindicated. Prohibited combination due to the high risk of severe adverse reactions. A mandatory time interval must pass after stopping one medicine before starting the other.
Other Serotonergic Agents Avoid or Use with Extreme Caution. Co-administration with agents that increase serotonin levels (e.g., triptans, tramadol, certain other antidepressants, Linezolid, St. John's Wort) requires close patient observation.
Agents Affecting Hemostasis Use with Caution and Monitoring. Concomitant use with medicines known to increase the risk of bleeding (e.g., NSAIDs, warfarin, antiplatelet drugs) requires caution due to an officially documented increased bleeding risk.
QT-Prolonging Agents Avoid. Co-administration with other medicines known to prolong the QT interval may increase the risk of serious cardiac issues.
CYP2C19 Inhibitors Caution Required. Medicines that strongly inhibit the CYP2C19 enzyme (e.g., omeprazole, cimetidine) can increase Finamed exposure, requiring caution and potentially monitoring.

These statements define the necessary restrictions and constraints, such as required washout periods and mandated patient monitoring, to manage the officially recognized pharmacodynamic (additive effect) and pharmacokinetic (metabolic inhibition) interaction risks.

Mechanism of Action

The mechanism of action for Finamed (Finasteride) operates exclusively at the level of hormone conversion and signaling, directly targeting key enzymatic activity, resulting in specific physiological effects.

Finasteride functions as a specific, mechanism-based inhibitor of the Type II 5-alpha reductase enzyme, which is responsible for the conversion of Testosterone into the highly active androgen, Dihydrotestosterone (DHT). By forming a highly stable, non-functional complex with this enzyme, the drug physically blocks the crucial step in the androgen hormone metabolism pathway. This molecular action causes a substantial and prolonged reduction in local and systemic DHT concentrations.

The primary physiological consequence is the attenuation of potent androgen signaling in responsive tissues. Because DHT is a substantially more active ligand than Testosterone for the intracellular androgen receptor, its diminished presence reduces the overall androgenic stimulus on specific cells, modifying cellular processes such as proliferation and tissue activity.

The mechanism demonstrates high selectivity for the Type II isoenzyme, which means it has minimal effect on the Type I 5-alpha reductase isoenzyme (predominant in other body areas). Maintenance of the mechanistic effect requires continuous exposure due to the very slow turnover of the inactivated enzyme complex, ensuring the necessary enzyme blockade over time.

Dosage and Administration Information

How to Use Finamed: Administration Guidelines

Finamed (Finasteride) is a prescription-only medication administered exclusively by the oral route as a film-coated tablet, following standardized regimens. The proper usage involves consistent, long-term administration tailored to the specific condition being addressed.


Standard Dosing and Frequency

The dosage of Finasteride is standardized across two distinct strengths, with treatment requiring a once-daily schedule.

Approved Indication Dosage Strength Daily Frequency
Benign Prostatic Hyperplasia (BPH) 5 mg tablet Once daily
Androgenetic Alopecia (AGA) 1 mg tablet Once daily

Administration Protocol and Duration

The tablets may be taken with or without meals for flexibility. To ensure proper dose delivery, the film-coated tablets must be swallowed whole and should not be crushed, broken, or chewed. This is a special procedural condition outlined in the prescribing information.

Treatment is characterized by a long-term duration. For BPH, a minimum of six months of continuous use is generally necessary to evaluate clinical response, with therapy often continued indefinitely. Similarly, for AGA, continued daily use is required to maintain the benefit, as discontinuation results in a gradual reversal of effect over several months.

If a dose is missed, the standard protocol is to skip the missed dose and simply resume the regular schedule the following day, rather than doubling the dose. No dosage adjustments are specified for older adults or individuals with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Finamed (Finasteride)

This section provides an overview of the official research, including the types of studies conducted and the outcomes that were measured, without offering clinical guidance or making claims about drug performance.


Evidence for Use in Benign Prostatic Hyperplasia (BPH)

Finamed was evaluated in adult males for Benign Prostatic Hyperplasia (BPH). The foundational research includes numerous large-scale Randomized Controlled Trials (RCTs), which compared study groups against those receiving an inactive placebo. Research examined multiple outcomes related to physical discomfort and systemic or functional imbalance. Studies monitored changes in standardized symptom scoring systems, the patient's maximum urinary flow rate, and ultrasound-based changes in the size of the prostate gland. Researchers also tracked the recording of BPH-related events, such as the need for related surgical procedures.

Findings describe patterns observed in the studies where research explored measurements related to prostate volume and BPH-related event recordings between the study groups and the placebo groups. This research contributes to the broader evidence landscape by exploring how BPH symptoms and the condition's measured parameters change over defined time intervals. Follow-up durations were limited in the core comparative trials, leading to uncertainty in long-term effects beyond seven years for those specific study designs.


Evidence for Use in Androgenetic Alopecia (AGA)

Finamed was evaluated in adult males for Androgenetic Alopecia (AGA), or male pattern hair loss. This research primarily involved placebo-controlled Randomized Controlled Trials (RCTs), supplemented by observational extension studies. Studies explored outcomes reflecting daily functioning and appearance, using objective metrics like the Target Area Hair Count (TAHC) and photographic assessments.

The trials report how symptoms evolved in the observed populations, documenting measurements over time related to hair count and hair density between the study groups and the placebo groups. Research describes that the study design for observed changes in hair parameters involved a requirement for continuous, long-term observation to be established. Subgroup findings are uncertain when moving outside the parameters of the populations specifically evaluated in the major trials (e.g., men with advanced AGA).

Key Studies & References

  1. Finasteride versus placebo for treatment of male pattern hair loss: a meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Finamed (FAQ)


Q: Are there any specific foods or drinks to avoid while taking Finamed?

Official product information states that Finamed may be taken with or without food for administration flexibility. Furthermore, regulatory guidance generally does not list alcohol consumption or specific foods as restrictions while using the medicine.


Q: Can Finamed be used by people with a history of heart problems?

Official labeling contains warnings and cautions that indicate the potential for use is a matter for individual assessment by a healthcare professional if a patient has a history of certain pre-existing cardiovascular conditions. Regulatory documents advise caution due to possible interactions with some heart-related medicines.


Q: Is it okay to drink alcohol in moderation while on Finamed?

Official regulatory information does not typically list alcohol as a restriction or contraindication when taking Finamed. No specific restriction on alcohol consumption is typically noted in the drug's labeling.


Q: Can Finamed be taken with antacids or heartburn medication?

Specific prescription medications used for heartburn (classified as CYP2C19 inhibitors) may increase Finamed exposure, which may lead to a need for caution and monitoring. General antacids are not usually listed as a formal interaction risk in the product information.


Q: Are there any common supplements that should be avoided while on Finamed?

Official regulatory documentation notes the need for caution or avoidance regarding certain herbal supplements like St. John's wort due to their potential for drug interactions. Most other over-the-counter supplements have not been formally studied for interaction effects with Finamed.


Q: What should a patient tell their doctor before starting Finamed?

The patient's disclosure to their healthcare professional includes conditions such as known allergies to the components of the pill. Official information indicates the need to report a history of liver problems or certain mood disorders, such as depression. Female handlers should also be aware of official information regarding pregnancy status or potential for pregnancy.


Q: How quickly can someone expect Finamed to start working?

Official studies indicate that while the drug begins to work on DHT hormone levels within a few hours of administration, the resulting clinical improvements take much longer. Noticeable improvement in symptoms or condition generally requires several months of continuous daily use.


Q: How long does Finamed usually stay in the system after the last dose?

The medicine is processed by the liver and eliminated from the body over time. The mean terminal half-life—the time it takes for half the medicine to leave the system—is approximately 5 to 6 hours in most adult males.


Q: Is Finamed a controlled substance?

Regulatory classification documents state that Finamed (Finasteride) is not designated as a controlled medication. It is classified as a prescription-only drug.


Q: Is it normal to feel a bit tired when starting Finamed?

Official product information lists possible side effects based on clinical trials and post-marketing surveillance. Although tiredness (or fatigue) is not listed as a common or frequent side effect, it has been noted in reports gathered through post-marketing surveillance.


Q: Does Finamed affect sleep patterns?

Official regulatory information on side effects does not typically list changes to sleep patterns as a common occurrence. However, insomnia (difficulty sleeping) has been reported in post-marketing surveillance reports.


Q: Can Finamed be taken with common vitamin supplements?

Official regulatory guidance suggests that most vitamin supplements have not been studied for interactions with Finamed. Caution is addressed in the regulatory guidance, as only prescription medicines are formally tested for potential interaction effects during the approval process.


Q: Does Finamed have any warnings about driving or operating machinery?

Official labeling indicates that Finamed is not generally expected to affect the user's ability to drive, operate machinery, or perform tasks requiring mental alertness.


Q: What are the ingredients in the Finamed pill besides the active component?

The active component of the drug is finasteride. The complete list of inactive ingredients (known as excipients) is detailed in the official package insert or product information document for the specific formulation.


Q: Can Finamed be stopped suddenly, or does it require gradual tapering?

Official regulatory labeling generally indicates that Finamed can be stopped abruptly without the need for a gradual dose reduction, known as tapering. However, the beneficial effects of the medicine will gradually reverse upon discontinuation.


Q: Does Finamed cause any change in appetite?

Official product information does not list changes in appetite as a common side effect. However, reports of a lack of appetite have been noted in post-marketing surveillance.


Q: Is Finamed known to cause confusion or memory issues?

Official documents contain post-marketing reports of adverse reactions in the psychiatric and neurological categories. These reports have included symptoms such as confusion and memory impairment.


Q: How is Finamed eliminated from the body?

The medicine is processed by the body primarily in the liver and subsequently eliminated. The elimination route for the processed drug involves both urine and feces.


Q: Does Finamed affect blood pressure levels?

Studies reviewed by regulatory bodies indicate that Finamed is not typically associated with causing changes in blood pressure levels when used on its own.


Q: Are generic versions of Finamed available, and are they the same?

Yes, generic versions containing the active ingredient finasteride are available following regulatory approval of the generic drug. Regulatory standards mandate that these generics demonstrate bioequivalence (meaning they are absorbed similarly to the original product).

How should Finamed be stored and disposed of?

How to Store and Dispose of Finamed?

Finasteride (Finamed) tablets must be stored according to official regulatory specifications to maintain product integrity and ensure safety.

Storage Conditions

The medication must be stored at a controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions. Tablets must be protected from light and moisture and must not be frozen. It is required to store the medication in its original container, and it must be kept out of the reach of children.

Handling and Disposal

Pregnant women or women who may be pregnant must not handle crushed or broken tablets. For disposal of unused or expired Finasteride, patients should consult a healthcare professional. Disposal is preferentially managed through a drug take-back program. If unavailable, tablets should be sealed with an undesirable substance (e.g., used coffee grounds) and placed in the household trash, as Finasteride is not recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Finamed found in:

A-Z Index: